ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 112 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,768,771 | -33.9% | 696,171 | 0.0% | 1.46% | +15.2% |
Q2 2023 | $7,219,293 | +28.2% | 696,171 | 0.0% | 1.27% | +8.8% |
Q1 2023 | $5,632,023 | -48.6% | 696,171 | 0.0% | 1.16% | -50.7% |
Q4 2022 | $10,964,693 | +0.1% | 696,171 | 0.0% | 2.36% | -7.6% |
Q3 2022 | $10,958,000 | +12.7% | 696,171 | 0.0% | 2.56% | -1.4% |
Q2 2022 | $9,719,000 | -29.0% | 696,171 | -12.3% | 2.59% | -24.8% |
Q1 2022 | $13,692,000 | +18.6% | 794,171 | 0.0% | 3.45% | +53.9% |
Q4 2021 | $11,547,000 | -19.2% | 794,171 | 0.0% | 2.24% | -0.1% |
Q3 2021 | $14,295,000 | +2.5% | 794,171 | 0.0% | 2.24% | +30.3% |
Q2 2021 | $13,946,000 | -45.9% | 794,171 | -22.3% | 1.72% | -63.8% |
Q1 2021 | $25,770,000 | +192.3% | 1,022,612 | -25.0% | 4.75% | +435.9% |
Q4 2020 | $8,816,000 | +59.3% | 1,362,612 | -36.7% | 0.89% | -42.6% |
Q3 2020 | $5,534,000 | +31.0% | 2,153,265 | -17.4% | 1.54% | +13.6% |
Q2 2020 | $4,225,000 | +55.8% | 2,608,117 | 0.0% | 1.36% | -12.9% |
Q1 2020 | $2,712,000 | – | 2,608,117 | – | 1.56% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |